1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Praxis’s Relutrigine May Offer Hope For Rare, Deadly Childhood Epilepsies

 
• By Joseph Haas

With Phase II data in two rare forms of developmental and epileptic encephalopathy, Praxis is moving to produce registrational data while hoping longer term to treat a broader range of DEE patients.

Epileptic seizure
Praxis reports positive data in two rare forms of pediatric epilepsy • Source: Shutterstock

Focused on treating rare forms of epilepsy, Praxis Precision Medicines, Inc. reported Phase II proof-of-concept data on 3 September that it believes will position relutrigine (PRAX-562), a selective inhibitor of persistent sodium current, for near-term approval in two rare but severe forms of developmental and epileptic encephalopathy (DEE) and longer-term for a large range of DEE sufferers.

Key Takeaways

  • Praxis’s Phase II data for persistent sodium current inhibitor relutrigine shows an ability to reduce monthly seizures by 46% in two rare forms of pediatric epilepsy

Praxis CEO Marcio Souza talked on a 3 September call with analysts about relutrigine’s promise to address DEE patients with high seizure burden and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

More from R&D

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.